About this Research Topic
Alcohol consumption is an important social, economic, and health problem. Heavy alcohol consumption results in a wide range of multi-organ pathology, including alcoholic liver disease (ALD) which is a major cause of alcohol-related morbidity and mortality in the United States and Worldwide. The clinical spectrum of ALD ranges from fatty liver to alcoholic hepatitis, fibrosis and cirrhosis, which may progress even further to hepatocellular carcinoma. ALD has limited prevention and therapeutic options. Therefore, understanding the molecular mechanism(s) that mediate the development and progression of alcohol-induced liver pathology, as well as identifying new biomarkers, therapeutic targets and promising novel therapeutic agents to prevent, manage, or reverse the disease progression, is of paramount importance.
We welcome contributions on the pathogenesis and treatment options for alcoholic liver disease that are currently available or in the pipe-line. We are soliciting contributions from experts in the field of hepatology, pathology, epidemiology, genetics, biochemistry, pharmacology, molecular biology to provide new information on the roles of diverse factors (genetic polymorphisms, drinking pattern, gender, epigenetic changes, alterations in methionine metabolism, cellular communications, dietary habits, intestinal dysbiosis, adipose dysfunction, viral/bacterial infections) that can promote the pathogenesis and progression of ALD as well as data on new biomarkers and their implications for diagnosis and therapy for ALD.
Potential topics include but not limited to the following:
- Pathogenesis of Alcoholic Liver Disease
- Spectrum of Alcoholic Liver Disease
- Alcoholic Hepatitis
- Cell- to-cell Communications within Liver in ALD progression
- Role of other organs in ALD progression/Organ-organ Interplay
- Second Hits in ALD progression (Metabolic syndrome, Bacterial/Viral/Drugs)
- Treatment Options
Types of Manuscripts
- Review Articles
- Original Research
- Short -Communications
- Clinical Studies
Please note that clinical studies/trials, manuscripts relating to hepatocellular carcinoma and other cancer-related/focused submissions will not be accepted through Frontiers in Physiology. Authors should instead consider submitting to this Research Topic via Frontiers in Pharmacology or Frontiers in Medicine.
Topic Editor Dr. Ashwani K Singal has provided consulting services for Novartis Pharmaceuticals, Merck Pharmaceuticals, Recordati Pharmaceuticals, Gilead Pharmaceuticals and Alnylam Pharmaceuticals. None of these pose any conflict of interest with regards to Research Topic subject. The other Topic Editors have declared no competing interests with regards to the Research Topic subject.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.